PC
VIRX

Pomelo Capital’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Pomelo Capital’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-119
Closed -$179K – 100
2014
Q3 		$179K Hold
119
– – 0.1% 45
2014
Q2 		$163K Hold
119
– – 0.08% 49
2014
Q1 		$165K Buy
+119
New +$138K 0.08% 47

Other funds holding VIRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Pomelo Capital's VIRX Position: Q4 2014 in Review

Pomelo Capital sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2014, closing a stake of 119 shares — an estimated $179K sold.

Pomelo Capital first reported a position in VIRX in Q1 2014 and held it in 3 quarters. The position peaked at $179K in Q3 2014. 78 funds tracked by Wall St. Rank hold VIRX as of Q4 2014.

  • Pomelo Capital reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2014 after selling out during the quarter.
  • Pomelo Capital sold 119 Viracta Therapeutics, Inc. Common Stock shares in Q4 2014, an estimated $179K.
  • Pomelo Capital first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2014 and held it in 3 quarters.
  • Pomelo Capital's Viracta Therapeutics, Inc. Common Stock position peaked at $179K in Q3 2014.
  • 78 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2014.

Based on Pomelo Capital's 13F filing for Q4 2014, filed 13 Feb 2015.